Vipadenant
CAS: 442908-10-3
Ref. 3D-SSA90810
5mg | Discontinued | ||
10mg | Discontinued | ||
25mg | Discontinued | ||
50mg | Discontinued | ||
100mg | Discontinued |
Product Information
Vipadenant is a new drug that has been developed for the treatment of cancer. It is a GABA-A receptor antagonist and has been shown to inhibit the proliferation of glioma cells in vitro and in vivo. Vipadenant also inhibits dopamine production, which may be responsible for its anti-cancer properties. This drug has been studied in clinical trials involving patients with recurrent gliomas, and it was found to be well tolerated with few side effects. Vipadenant inhibits the growth of tumor cells by interfering with the energy metabolism within the tumor cell, leading to cell death.